Ilkay Bozkurt

Ilkay Bozkurt

Auto-generated profile, based on publicly available information

Ilkay Bozkurt

Ondokuz Mayis Univ, Sch Med, Dept Infect Dis & Clin Microbiol, Samsun, Turkiye

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2021 in Travel Medicine and Infectious Disease
Verified
Journal Article
Closed access
FSFatma Nurhayat Saydam
Fatma Nurhayat Saydam
HEHakan Erdem
Hakan Erdem
HAHandan Ankarali
Handan Ankarali
MRManar Ezz El-Arab Ramadan
Manar Ezz El-Arab Ramadan
NENagwa Mostafa El-Sayed
Nagwa Mostafa El-Sayed
Alfonso J. Rodriguez-MoralesAlfonso J. Rodriguez-Morales
Alfonso J. Rodriguez-Morales

2 April 2012 in Our Dermatology Online
Verified
Journal Article
Open access
IBIlkay Bozkurt
Ilkay Bozkurt
EYEfsan Yontar
Efsan Yontar
MDMehmet Doganay
Mehmet Doganay

29 December 2023 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Open access
HCHatun Ozturk Cerik
Hatun Ozturk Cerik
LÖLatif Mustafa Özbek
Latif Mustafa Özbek
BOBetul altintas oner
Betul altintas oner
IBİlkay Bozkurt
İlkay Bozkurt
Objective: Brucellosis is one of the most prevalent zoonoses worldwide and is endemic in Türkiye. It is a multisystemic infection that can affect various organ systems. Epididymo-orchitis is the most common form of genitourinary involvement. This study aimed to evaluate the incidence, clinical characteristics, laboratory values, and treatment outcomes of brucellar epididymo-orchitis (BEO) in the East Anatolian region, where brucellosis is hyperendemic. Materials and Methods: This study was conducted between January 1, 2018, and April 30, 2019. All male patients diagnosed with brucellosis at the infectious disease clinic were evaluated for epididymo-orchitis according to clinical findings (testicular pain, swelling, erythema). In addition, to identify BEO patients, all epididymo-orchitis cases admitted to the urology outpatient clinic according to the study protocol were referred to the infectious diseases clinic for Brucella infection. Patients were enrolled prospectively, and data were analyzed retrospectively. Results: Brucella infection was diagnosed in 326 patients during the study period, of whom 208 (63.8%) were male. Brucellar epididymo-orchitis was diagnosed in 18 patients at the end of sixteen months. The incidence of epididymo-orchitis in patients with Brucella infection was 8.7%. The mean age of the patients was 36.9±11.5 years. The majority of patients had occupational animal contact (83.3%) and consumption of fresh cheese made from raw milk (55.5%). Acute brucellosis was diagnosed in 17 (94.4%) patients; all patients presented with scrotal pain and swelling. Unilateral epididymo-orchitis was observed in 16 (88.8%) patients. Most patients (88.3%) applied to outpatient clinics other than infectious diseases, especially the urology clinic (77.7%). Double or triple combined treatments with aminoglycoside/doxycycline/rifampicin were given to the patients. Hydrocelectomy was performed in three patients, orchiectomy in one patient, and relapse was seen in one patient. Conclusion: Brucella infection should be considered in patients presenting with epididymo-orchitis in endemic regions. Awareness of brucellosis by urologists will ensure that the disease is diagnosed without complications. Keywords: Brucellosis, epididymo-orchitis, epidemiology

23 December 2021 in Viral Hepatitis Journal
Verified
Journal Article
Closed access
FTFehmi Tabak
Fehmi Tabak
GŞGöktuğ Şirin
Göktuğ Şirin
MDMehmet Demir
Mehmet Demir
MAMurat Aladag
Murat Aladag
SSSua Sumer
Sua Sumer
RGRahmet Güner
Rahmet Güner

15 November 2022 in Turkish Journal of Gastroenterology
Verified
Journal Article
Open access
FYFigen Sarıgül Yıldırım
Figen Sarıgül Yıldırım
ÜÜÜlkü Üser
Ülkü Üser
NSNagehan Didem Sarı
Nagehan Didem Sarı
BKBehice Kurtaran
Behice Kurtaran
YÖYusuf Önlen
Yusuf Önlen
FTFehmi Tabak
Fehmi Tabak
Background: People who inject drugs (PWID) should be treated in order to eliminate hepatitis C virus in the world. The aim of this study was to compare direct-acting antivirals treatment of hepatitis C virus for PWID and non-PWID in a real-life setting. Methods: We performed a prospective, non-randomized, observational multicenter cohort study in 37 centers. All patients treated with direct-acting antivirals between April 1, 2017, and February 28, 2019, were included. In total, 2713 patients were included in the study among which 250 were PWID and 2463 were non-PWID. Besides patient characteristics, treatment response, follow-up, and side effects of treatment were also analyzed. Results: Genotype 1a and 3 were more prevalent in PWID-infected patients (20.4% vs 9.9% and 46.8% vs 5.3%). The number of naïve patients was higher in PWID (90.7% vs 60.0%), while the number of patients with cirrhosis was higher in non-PWID (14.1% vs 3.7%). The loss of follow-up was higher in PWID (29.6% vs 13.6%). There was no difference in the sustained virologic response at 12 weeks after treatment (98.3% vs 98.4%), but the end of treatment response was lower in PWID (96.2% vs 99.0%). In addition, the rate of treatment completion was lower in PWID (74% vs 94.4%). Conclusion: Direct-acting antivirals were safe and effective in PWID. Primary measures should be taken to prevent the loss of follow-up and poor adherence in PWID patients in order to achieve World Health Organization’s objective of eliminating viral hepatitis Cite this article as: Sarıgül Yıldırım F, Üser Ü, Sarı ND, et al. In a real-life setting, direct-acting antivirals to people who inject drugs with chronic hepatitis C in Turkey. Turk J Gastroenterol. 2022;33(11):971-978

16 September 2019 in Dicle Tıp Dergisi
Verified
Journal Article
Open access
IBİlKay Bozkurt
İlKay Bozkurt
ABAhmet Bektaş
Ahmet Bektaş
Amaç: Anti-tümör nekrozis faktör alfa (anti-TNF) alfa kullanan HBsAg pozitif hastalarda profilaksi önerilmektedir. HbsAg (-), anti-HBcIgG ( +/-) ve anti-HBsIgG (-)hastalarda ise hepatit B profilaksisi tartışmalıdır. Bu çalışmada anti-TNF alfa kullanan hastalarda HBV tarama oranı ve reaktivasyon sıklığının saptanması amaçlanmıştır.Yönetmler: Çalışma tek merkezde retrospektif olarak yürütülmüştür. Farklı endikasyonlarla anti-TNF alfa kullanan hastalarda tedavi öncesi hepatit B göstergeleri (HBsAg, anti-HBcIgG, anti-HBs) ile viral yük tetkik sonuçları elektronik dosya kayıtlarından taranmıştır.Bulgular: Farklı endikasyonlarla anti-TNF alfa kullanan 644 hasta çalışmaya alınmıştır. Bu hastaların 410’u (%63,7) tedavi öncesinde hepatit B açısından taranmıştır. (410 hastanın 17’si HBsAg (+) (grup 1), 39’u HBsAg (-), anti-HBs(+) ve anti-HBcIgG (+) (grup 2), 15’i izole anti-HBcIgG (+) (grup 3), 339‘u viral göstergeleri negatif (grup 4) olarak saptanmıştır). Hastalar ortalama 28 ay süreyle takip edilmiştir. Grup 1 hastaların 13’ü (%76), grup 2 ve 3’deki hastaların ise 48’i (%88,9) reaktivasyon açısından takip edilmiştir. Grup 2 ve 3’deki hastaların hiçbirisinde takiplerinde HBV reaktivasyonu gelişmezken, grup 1 hastalarının birinde reaktivasyon gelişmiştir. Anti-TNF öncesinde tarama yapılmayan bir hastada da reaktivasyon tespit edilmiştir.Sonuç: Anti-TNF alfa alan hastaların reaktivasyon açısından tarama ve takibinin doğru zamanda ve uygun testlerle yapılması ve hastaların yakın izlemi gerekmektedir.